Niemann-Pick Type C Disease - Pipeline Insight, 2021

September 2021 | 60 pages | ID: NFD654EF9122EN
DelveInsight

Abstracts

This report can be delivered to the clients within 48-72 hours

DelveInsight’s, “Niemann-Pick Type C Disease – Pipeline Insight, 2021,” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Niemann-Pick Type C Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Niemann-Pick Type C Disease Understanding

Niemann-Pick Type C Disease: Overview

Niemann-Pick disease type C (NPC) is a rare progressive genetic disorder characterized by an inability of the body to transport cholesterol and other fatty substances (lipids) inside of cells. NPC belongs to a larger group of more than 50 disorders known as lysosomal storage disorders. This leads to the abnormal accumulation of these substances within various tissues of the body, including brain tissue. Individuals with NPC can have onset of symptoms at different ages that have been grouped historically as: perinatal (shortly before and after birth), early infantile (3 months to < 2 years), late infantile (2 to < 6 years), juvenile (6 to < 15 years), and adult (15 years and greater). Individuals with NPC have mutations in one of two genes, NPC1 or NPC2 and are inherited in an autosomal recessive manner. Approximately 95% of affected individuals have mutations in NPC1. Niemann-Pick disease type C is diagnosed based on characteristic symptoms obtained from a thorough clinical evaluation, and confirmed by a variety of specialized tests. Proper diagnosis of NPC requires physicians to suspect the diagnosis based upon symptoms, and to follow up with appropriate laboratory tests to evaluate the function of the protein or the presence of accumulated byproducts (biochemical tests), and to identify mutations in the NPC1 or NPC2 gene (gene sequencing). Current treatment is directed toward the specific symptoms apparent in each individual. Several therapies have been studied or are currently being studied to assess their long-term safety and effectiveness as potential treatments for individuals with NPC.

'Niemann-Pick Type C Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Niemann-Pick Type C Disease pipeline landscape is provided which includes the disease overview and Niemann-Pick Type C Disease treatment guidelines. The assessment part of the report embraces, in depth Niemann-Pick Type C Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Niemann-Pick Type C Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Niemann-Pick Type C Disease R&D. The therapies under development are focused on novel approaches to treat/improve Niemann-Pick Type C Disease.

Niemann-Pick Type C Disease Emerging Drugs Chapters

This segment of the Niemann-Pick Type C Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Niemann-Pick Type C Disease Emerging Drugs

• Arimoclomol: Orphazyme

Arimoclomol is an investigational drug candidate that amplifies the production of heat-shock proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is in clinical development at Orphazyme for the treatment of NPC and Gaucher disease. Arimoclomol has received orphan drug designation for NPC in the US and EU, as well as fast-track designation from the US Food and Drug Administration (FDA) for NPC. In addition, arimoclomol has received breakthrough therapy designation and rare-pediatric disease designation from the FDA for NPC. Orphazyme has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C (NPC). The FDA issued the CRL based on needing additional qualitative and quantitative evidence to further substantiate the validity and interpretation of the 5-domain NPC Clinical Severity Scale (NPCCSS) and, in particular, the swallow domain. Further, the FDA noted in the CRL that additional data are needed to bolster confirmatory evidence beyond the single phase II/III clinical trial to support the benefit-risk assessment of the NDA.

• Adrabetadex: Mandos, LLC

VTS-270 (Mallinckrodt) also known as Kleptose; 2-Hydroxypropyl- beta-cyclodextrin; HP-beta- CD; HPBCD) is under development. The drug has received various designations from the United States Food Drug and Administration (FDA)-Rare Pediatric Disease Designation, Promising Innovative Medicine (PIM) Designation, Breakthrough Therapy Designation and Orphan Drug Designation for the treatment of NPC. VTS-270 is currently in phase III stage of development, an intrathecal preparation that can cross the Blood Brain Barrier (BBB) and as a result, it targets the neurological symptoms of NPC such as dementia and cataplexy. In May 2021, Mandos, LLC announced they have entered into an agreement with Vtesse, LLC, a wholly owned subsidiary of Mallinckrodt Pharmaceuticals (Mallinckrodt), a global biopharmaceutical company, to acquire adrabetadex (also known as VTS-270), a drug in development for the treatment of Niemann-Pick Type C1 disease (NPC1).

Further product details are provided in the report.

Niemann-Pick Type C Disease: Therapeutic Assessment

This segment of the report provides insights about the different Niemann-Pick Type C Disease drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Niemann-Pick Type C Disease

There are approx. 10+ key companies which are developing the therapies for Niemann-Pick Type C Disease. The companies which have their Niemann-Pick Type C Disease drug candidates in the most advanced stage, i.e. Preregistration include, Orphazyme.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Niemann-Pick Type C Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Niemann-Pick Type C Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Niemann-Pick Type C Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Niemann-Pick Type C Disease drugs.

Niemann-Pick Type C Disease Report Insights

• Niemann-Pick Type C Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Niemann-Pick Type C Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Niemann-Pick Type C Disease drugs?
• How many Niemann-Pick Type C Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Niemann-Pick Type C Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Niemann-Pick Type C Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Niemann-Pick Type C Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Contents

Introduction
Executive Summary
Niemann-Pick Type C Disease: Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Late Stage Products (Preregistration)
  Comparative Analysis
Arimoclomol: Orphazyme
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
  Comparative Analysis
IB1001: IntraBio
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report.
Preclinical stage products
  Comparative Analysis
Research programme: Niemann-Pick disease gene therapies - Sarepta Therapeutics/StrideBio
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report.
Inactive Products
  Comparative Analysis
Niemann-Pick Type C Disease Key Companies
Niemann-Pick Type C Disease Key Products
Niemann-Pick Type C Disease- Unmet Needs
Niemann-Pick Type C Disease- Market Drivers and Barriers
Niemann-Pick Type C Disease- Future Perspectives and Conclusion
Niemann-Pick Type C Disease Analyst Views
Niemann-Pick Type C Disease Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Niemann-Pick Type C Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Niemann-Pick Type C Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products